Chaker Layal, Baumgartner Christine, den Elzen Wendy P J, Collet Tinh-Hai, Ikram M Arfan, Blum Manuel R, Dehghan Abbas, Drechsler Christiane, Luben Robert N, Portegies Marileen L P, Iervasi Giorgio, Medici Marco, Stott David J, Dullaart Robin P, Ford Ian, Bremner Alexandra, Newman Anne B, Wanner Christoph, Sgarbi José A, Dörr Marcus, Longstreth W T, Psaty Bruce M, Ferrucci Luigi, Maciel Rui M B, Westendorp Rudi G, Jukema J Wouter, Ceresini Graziano, Imaizumi Misa, Hofman Albert, Bakker Stephan J L, Franklyn Jayne A, Khaw Kay-Tee, Bauer Douglas C, Walsh John P, Razvi Salman, Gussekloo Jacobijn, Völzke Henry, Franco Oscar H, Cappola Anne R, Rodondi Nicolas, Peeters Robin P
Departments of Internal Medicine (R.P.P., L.C., M.M.) and Epidemiology (R.P.P., O.H.F., A.D., A.H., A.I., L.C., M.L.P.P.), Erasmus University Medical Center, 3000 DR Rotterdam, The Netherlands; Rotterdam Thyroid Center (R.P.P., L.C., M.M.) and Department of Radiology and Neurology (M.A.I.), Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands; Department of General Internal Medicine (N.R., C.B., M.R.B.), Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Service of Endocrinology, Diabetes, and Metabolism (T.-H.C.), University Hospital of Lausanne, 1011 Lausanne, Switzerland; Departments of Clinical Chemistry and Laboratory Medicine (W.P.J.d.E.), Public Health and Primary Care (J.G.), and Cardiology (W.J.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Departments of Medicine and Epidemiology and Biostatistics (D.C.B.), University of California, San Francisco, San Francisco, California 94143; Division of Endocrinology, Diabetes, and Metabolism (A.R.C.), Department of Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104; Department of Epidemiology (A.H.), Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115; Department of Endocrinology (S.R.), Gateshead Health Foundation National Health Service Trust, Gateshead, SE18 4QH, United Kingdom; Department of Endocrinology and Diabetes (J.P.W.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Schools of Medicine and Pharmacology (J.P.W.) and Population Health (A.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; National Council Research Institute of Clinical Physiology (G.I.), 56124 Pisa, Italy; Robertson Centre for Biostatistics (I.F.) and Institute of Cardiovascular and Medical Sciences (D.J.S.), Faculty of Medicine, University of Glasgow, Glasgow G12 8TA, United Kingdom; Department of Epidemiology (A.B.N.), University of Pittsburgh, Pittsburgh, Pennsylvania 15260; Department of Internal Medicine (S.J.L.B., R.P.D.), University Medical Center, University of Groningen, 9700 AB Groningen, The Netherlands; Department of Medicine (C.W., C.D.), Division of Nephrology, University Hospital of Würzburg, and Comprehensive Heart Failure Centre (C.W., C.D.), 97070 Würzburg, Germany; Department of Clinical Studies (M.I.), Radiation Effects Research Foundation, Nagasaki 850-8555, Japan; Department of Clinical and Experimental Medicine (G.C.), University of Parma, 143100 Parma, Italy; National Institute on Aging (L.F.), Baltimore, Maryland 21225; Institute for Community Medicine (H.V.), Clinical-Epidemiological Research/Study of Health in Pomerania, University Medicine, German Centre of Cardiovascular Research, Partner Site, Department of Internal Medicine (M.D.), and University Medicine (M.D.), German Centre of Cardiovascular Research, Partner Site, 17487 Greifswald, Germany; Departments of Neurology and Epidemiology (W.T.L.), and Cardiovascular Health Research Unit (W.T.L.), Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, Washington 98108; Group Health Research Institute (B.M.P.), Group Health Cooperative, Seattle, Washington 98101; Division of Endocrinology (R.M.B.M., J.A.S.), Department of Medicine, Federal University of Sao Paulo, 05508-900 São Paulo, Brazil; Division of Endocrinology (J.A.S.), Faculdade de Medicina de Marília, Marília, Brazil; Department of Public Health and Primary Care (R.N.L., K.-T.K.), University of Cambridge, Cambridge CB2 1TN, United Kingdom; Interuniversity Cardiology Institute of The Netherlands (W.J.), 3508 GA Utrecht, The Netherlands; School of Clinical and Experimental Medicine (J.A.F.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Public Health and Center for Healthy Ageing (R.G.W.), Faculty of Health and Medical Sciences, University of Copenhagen, DK-2400 Copenhagen, Denmark.
J Clin Endocrinol Metab. 2016 Nov;101(11):4270-4282. doi: 10.1210/jc.2016-2255. Epub 2016 Sep 7.
The currently applied reference ranges for thyroid function are under debate. Despite evidence that thyroid function within the reference range is related with several cardiovascular disorders, its association with the risk of stroke has not been evaluated previously.
We identified studies through a systematic literature search and the Thyroid Studies Collaboration, a collaboration of prospective cohort studies. Studies measuring baseline TSH, free T, and stroke outcomes were included, and we collected individual participant data from each study, including thyroid function measurements and incident all stroke (combined fatal and nonfatal) and fatal stroke. The applied reference range for TSH levels was between 0.45 and 4.49 mIU/L.
We collected individual participant data on 43 598 adults with TSH within the reference range from 17 cohorts, with a median follow-up of 11.6 years (interquartile range 5.1-13.9), including 449 908 person-years. Age- and sex-adjusted pooled hazard ratio for TSH was 0.78 (95% confidence interval [CI] 0.65-0.95 across the reference range of TSH) for all stroke and 0.83 (95% CI 0.62-1.09) for fatal stroke. For the free T analyses, the hazard ratio was 1.08 (95% CI 0.99-1.15 per SD increase) for all stroke and 1.10 (95% CI 1.04-1.19) for fatal stroke. This was independent of cardiovascular risk factors including systolic blood pressure, total cholesterol, smoking, and prevalent diabetes.
Higher levels of TSH within the reference range may decrease the risk of stroke, highlighting the need for further research focusing on the clinical consequences associated with differences within the reference range of thyroid function.
目前应用的甲状腺功能参考范围存在争议。尽管有证据表明参考范围内的甲状腺功能与多种心血管疾病有关,但其与中风风险的关联此前尚未得到评估。
我们通过系统的文献检索和甲状腺研究协作组(一个前瞻性队列研究的合作组织)确定了相关研究。纳入测量基线促甲状腺激素(TSH)、游离甲状腺素(free T)和中风结局的研究,并从每项研究中收集个体参与者数据,包括甲状腺功能测量值以及所有中风(包括致命性和非致命性)和致命性中风的发生率。TSH水平的应用参考范围为0.45至4.49 mIU/L。
我们从17个队列中收集了43598名TSH在参考范围内的成年人的个体参与者数据,中位随访时间为11.6年(四分位间距5.1 - 13.9),共449908人年。所有中风的TSH年龄和性别调整后的合并风险比为0.78(95%置信区间[CI]在TSH参考范围内为0.65 - 0.95),致命性中风为0.83(95% CI 0.62 - 1.09)。对于游离甲状腺素分析,所有中风的风险比为1.08(每标准差增加95% CI 0.99 - 1.15),致命性中风为1.10(95% CI 1.04 - 1.19)。这与包括收缩压、总胆固醇、吸烟和糖尿病患病率在内的心血管危险因素无关。
参考范围内较高水平的TSH可能降低中风风险,这凸显了进一步研究关注甲状腺功能参考范围内差异相关临床后果的必要性。